{'_data': [['Unknown',
            [['GI',
              u'abdominal pain, dyspepsia, constipation, dry mouth or throat, flatulence Not known pancreatitis Hepatobiliary disorders Not known hepatitis, jaundice Skin and subcutaneous tissue disorders Common facial oedema, purpura most often described as bruises resulting from physical trauma, rash, pruritus, acne Not known Stevens-Johnson syndrome, angioedema, erythema multiforme, alopecia, drug rash with eosinophilia and systemic symptoms Musculoskeletal and connective tissue disorders Common arthralgia, myalgia, back pain, twitching Not known myoclonus Renal and urinary disorder Not known acute renal failure, incontinence Reproductive system and breast disorders Common impotence Not known breast hypertrophy, gynaecomastia General disorders and administration site conditions Very Common fatigue, fever Common peripheral oedema, abnormal gait, asthenia, pain, malaise, flu syndrome Uncommon generalized oedema Not known withdrawal reactions (mostly anxiety, insomnia, nausea, pains, sweating), chest pain. Sudden unexplained deaths have been reported where a causal relationship to treatment with gabapentin has not been established. Investigations Common WBC (white blood cell count) decreased, weight gain Uncommon elevated liver function tests SGOT (AST), SGPT (ALT) and bilirubin Not known blood glucose fluctuations in patients with diabetes Injury,poisoning and procedural complications Common accidental injury, fracture, abrasion Under treatment with gabapentin cases of acute pancreatitis were reported. Causality with gabapentin is unclear (see section 4.4). In patients on haemodialysis due to end-stage renal failure, myopathy with elevated creatine kinase levels has been reported. Respiratory tract infections, otitis media, convulsions and bronchitis were reported only in clinical studies in children. Additionally, in clinical studies in children, aggressive behaviour and hyperkinesias were reported commonly.']]]],
 '_pages': [7, 9],
 u'_rank': 1,
 u'_type': u'LSFU'}